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For poorly soluble compounds, drug product performance in patients with Ulcerative Colitis 20 
(UC) compared to healthy subjects can be affected due to differences in drug solubility in GI 21 
fluids. A risk assessment tool was developed to identify compounds with a high risk of altered 22 
solubility in the GI fluids of UC patients. Pathophysiological changes impacting on the 23 
composition of GI fluids in UC patients were considered and UC biorelevant media 24 
representative of the stomach, intestine and colon were developed based on alteration of 25 
biorelevant media based on healthy subjects and literature data using a Design of Experiment 26 
approach. The UC media were characterised and revealed differences in surface tension, 27 
osmolality and buffer capacity compared to media based on healthy subjects. The solubility of 28 
six drugs was investigated in UC biorelevant media and results were related to media- and 29 
drug-dependent factors. A lower drug solubility in UC intestinal media was observed for 30 
compounds with a high lipophilicity. In UC simulated colonic fluids, drug solubility was 31 
altered for ionisable compounds. Additionally, a higher solubility of neutral lipophilic drugs 32 
was observed in UC fasted state colonic media with increased concentrations of soluble 33 
proteins. The developed UC biorelevant media offer the possibility to identify the risk of altered 34 
drug solubilisation in UC patients without conducting expensive clinical trials. A high risk was 35 
related to drug ionization properties and lipophilicity in the current study with all investigated 36 
drugs showing differences in solubility in biorelevant media based on UC patients compared 37 
to healthy subjects.  38 
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1. Introduction 42 
Ulcerative Colitis (UC), a main type of inflammatory bowel disease (IBD), is an 43 
autoinflammatory disorder that affects approximately 2.1 million people in Europe (Burisch et 44 
al., 2013). The inflammation manifests itself in ulcerations of the lining of the large intestine, 45 
which are confined to the mucosa and submucosa. Typically, the first appearance of the disease 46 
is limited to the rectum and further disease progression leads to a proximal extension to the 47 
colon. According to the disease location, the Montreal classification system groups UC in 48 
Ulcerative proctitis (rectum is affected), left-sided UC (a proportion of the colorectum distal to 49 
the splenic flexure is affected) or extensive colitis (entire large intestine is affected) (Silverberg 50 
et al., 2005). UC can also be grouped in four different disease states according to symptom 51 
severity: mild, moderate, severe or a state of clinical remission (Silverberg et al., 2005). 52 
The different states and locations of UC necessitate different treatment options and drug 53 
formulation approaches. The classic step-up approach includes aminosalicylates as first 54 
treatment option in mild to moderate UC (Berends et al., 2019). For this treatment, different 55 
drug formulations can be used based on disease location with suppositories and enemas for 56 
distal UC and/or controlled-release or prodrug formulations of mesalamine, when more 57 
proximal parts of the colon are affected. Corticosteroids are used to induce remission in 58 
moderate to severe disease states (Berends et al., 2019). Drug formulations include immediate-59 
release formulations of systemic corticosteroids or controlled-release formulations of the 60 
topical steroid budesonide (e.g., Uceris® [Santarus, San Diego, CA, USA]). For active UC, the 61 
next therapeutic option is a co-treatment with thiopurines such as azathioprine due to their slow 62 
onset of therapeutic action. Further treatment options are calcineurin inhibitors for severely 63 
active UC or monoclonal antibodies as the last therapeutic option (Berends et al., 2019). 64 
Additionally, several new treatment options are emerging: The oral JAK inhibitor tofacitinib 65 
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has been approved for the treatment of moderate to severe UC and several other small 66 
molecules are enrolling in phase III clinical trials (Ma et al., 2019).   67 
Consequently, drug delivery via the oral route is commonly used in UC for topical as well as 68 
systemic drug therapy. Other drugs which are prescribed more often in IBD patients than the 69 
general population include e.g., antidepressants, antibiotics and nonsteroidal anti-inflammatory 70 
analgesics (Haapamaki et al., 2013). Successful drug delivery via the oral route is dependent 71 
on gastrointestinal (GI) physiology and drug/formulation properties. Various processes such as 72 
drug release/dissolution, permeation through the GI membrane and gut or hepatic metabolism 73 
can be influenced by an altered GI physiology in UC (Bai et al., 2016; Effinger et al., 2019; 74 
Hatton et al., 2018, 2019). Since clinical trials to assess drug product performance in UC 75 
patients are rarely performed due to high costs, a heterogenous patient population and a high 76 
time effort, possible effects on the drug therapy of UC patients are not investigated in most 77 
cases. Therefore, alternative tools to predict drug product performance in UC patients are 78 
needed.   79 
In vitro release and dissolution testing can be used as surrogate for the in vivo performance of 80 
poorly soluble compounds with solubility- or dissolution rate-limited absorption (Amidon et 81 
al., 1995). For this purpose, biorelevant media have been developed based on healthy subjects 82 
to simulate GI fluids of different GI compartments and prandial states and to evaluate drug 83 
products in vitro (Galia et al., 1998; Jantratid et al., 2008; Markopoulos et al., 2015; Vertzoni 84 
et al., 2010a; Vertzoni et al., 2005). For colonic fluids, fasted and fed state conditions were 85 
considered as extreme conditions expected in a clinical study setting. Since UC can alter the 86 
GI fluid composition of patients, drug product performance could be affected for these drugs. 87 
The development of biorelevant media for UC patients would allow the identification of 88 
differences in drug solubility or dissolution compared to the biorelevant medium based on 89 
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healthy subjects, which would indicate a high risk of altered drug product performance in UC 90 
patients.  91 
This study aims to develop a risk assessment tool to identify compounds with a high risk of 92 
altered solubility in the GI fluids of UC patients. Pathophysiological changes impacting on the 93 
composition of GI fluids in UC patients were considered and UC biorelevant media 94 
representative of the stomach, intestine and colon were developed based on alteration of 95 
biorelevant media developed based on healthy subjects and literature data using a Design of 96 
Experiment approach. Subsequently, the developed UC biorelevant media were characterised 97 
according to their surface tension, osmolality, buffer capacity and dynamic viscosity and the 98 
solubility of six poorly soluble compounds with different physicochemical properties was 99 
determined in UC biorelevant media. To identify if certain drug characteristics contribute to a 100 
higher risk of altered drug solubility in GI fluids of UC patients, Partial least Squares (PLS) 101 
regression was used to correlate drug properties and media-dependent factors with the relative 102 
effect on drug solubility. 103 
2. Materials 104 
Acetic acid High Performance Liquid Chromatography (HPLC) grade, pepsin from porcine 105 
gastric mucosa, sodium oleate, α-D-glucose, budesonide, phosphoric acid and sodium 106 
hydroxide were purchased from Sigma-Aldrich Company Ltd., Dorset, England. Sulfasalazine, 107 
loperamide hydrochloride, dipyridamole, celecoxib, azathioprine, methanol HPLC grade and 108 
acetonitrile HPLC grade were purchased from VWR International Ltd, Lutterworth, UK. 109 
Tris(hydroxymethyl)aminomethane, hydrochloric acid 36.5–38%, sodium chloride, 110 
trifluoroacetic acid (TFA), potassium dihydrogen orthophosphate, bovine serum albumin 111 
protease free powder fraction V (BSA), dimethyl sulfoxide and maleic acid were used from 112 
Fisher Scientific UK Ltd., Loughborough, England. Other chemicals used included sodium 113 
taurocholate (Prodotti Chimici Alimentari S.P.A., Basaluzzo, Italy), egg lecithin–Lipoid EPCS 114 
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(Lipoid GmbH, Ludwigshafen, Germany), glyceryl monooleate–Rylo Mg 19 (Danisco, 115 
Brabrand, Denmark) and cholic acid sodium salt (VWR International Ltd, Lutterworth, UK). 116 
Water was ultra-pure (Milli-Q) laboratory grade. 117 
3. Methods 118 
3.1. Media development 119 
3.1.1. GI pathophysiological changes in UC patients integrated in the experimental 120 
design 121 
Information from literature was collected to identify differences in the composition of GI fluids 122 
of UC patients compared to healthy subjects. For studies with graphically displayed data, the 123 
relevant information was extracted with WebPlotDigitizer (Rohatgi, 2018). Apart from 124 
components and properties directly measured in the GI fluids of UC patients, an additional 125 
factor, namely the lecithin levels measured in the GI mucosa, was considered as indirect factor 126 
due to the limited number of studies performed in UC patients. All factors were integrated with 127 
two levels in the experimental design. The low and the high level were selected based on the 128 
available information on the respective parameter as described in Section 3.1.1.1-3.1.1.3. 129 
3.1.1.1. Lecithin concentration 130 
The lecithin concentration was included as an indirect factor in the experimental design of UC 131 
gastric, intestinal media and fed state colonic UC media. 132 
Lecithin is a constituent of the GI mucosa and essential to maintain the normal mucus barrier 133 
function. It has been shown that the lecithin concentration in the intestinal mucus barrier of 134 
patients with UC was decreased by over 70% compared to healthy subjects (Braun et al., 2009; 135 
Ehehalt et al., 2010). Considering the disease state, 6 investigated UC patients were in 136 
remission and 15 in relapse (Braun et al., 2009). The lecithin in the colonic mucus barrier is 137 
likely to be from secretions by jejunal and ileal enterocytes as investigated in rat intestinal 138 
perfusion studies (Ehehalt et al., 2004). Therefore, decreased lecithin concentrations are likely 139 
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to be present also in more proximal parts of the GI tract than the colon. The treatment of UC 140 
patients with a delayed-release oral formulation of lecithin has shown to increase the amount 141 
of lecithin in rectal mucus and reduce inflammatory activity (Stremmel et al., 2010). 142 
Lecithin is also an essential constituent of bile and can emulsify hydrophobic molecules due to 143 
its amphiphilic structure. Hepatobiliary manifestations are common in UC patients and include 144 
primary sclerosing cholangitis (PSC), small duct PSC, chronic hepatitis, cryptogenic cirrhosis, 145 
cholangiocarcinoma and cholelithiasis (Lichtenstein, 2011). The most common of these 146 
conditions is PSC with an incidence of 2.5 to 7.5% in patients with UC (Lichtenstein, 2011). 147 
PSC leads to the formation of bile duct strictures impeding the flow of bile to the intestine. 148 
Consequently, reduced bile salt and lecithin concentrations are likely to be present in the GI 149 
fluids of the affected UC patients. Decreased concentrations of bile acids and lecithin were 150 
already observed in intrahepatic bile specimens of patients with PSC (Gauss et al., 2013). 151 
Decreased lecithin concentrations in UC patients compared to healthy subjects were also 152 
observed in gallbladder bile in the fasted state obtained by cholecystokinin-stimulated, 153 
duodenal biliary drainage (Marks et al., 1977). 154 
Apart from the ascending colon fluid, no studies investigated the concentration of lecithin in 155 
the remaining luminal fluids of UC patients. Therefore, the lecithin levels for the DoE were 156 
based on an indirect percental approach in all media except UC-Fasted-State Simulated Colonic 157 
Fluid (FaSSCoF) according to 158 
𝑥𝑈𝐶−𝐵𝑀 = 0.30 ∗ 𝑥𝐻−𝐵𝑀          (1) 159 
where 𝑥𝑈𝐶−𝐵𝑀 is the low level of the lecithin concentration in UC media, 𝑥𝐻−𝐵𝑀 is the lecithin 160 
concentration in biorelevant media based on healthy subjects and the factor 0.30 represents the 161 
ratio of lecithin previously observed in the colonic mucus layer of UC patients compared to 162 
healthy subjects (Braun et al., 2009; Ehehalt et al., 2010). Therefore, the low lecithin level in 163 
UC biorelevant media is set to 30% of the concentration in corresponding healthy biorelevant 164 
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media and the high lecithin level corresponds to the concentration in biorelevant media based 165 
on healthy subjects.  166 
3.1.1.2. Fasted state ascending colon fluid 167 
The fasted state ascending colon fluid of UC patients in states of relapse and remission (defined 168 
based on the Clinical Rachmilewitz Index (CRI)) has previously been characterised (Vertzoni 169 
et al., 2010b). A higher osmolality was observed in patients with UC in remission compared to 170 
patients in relapse and healthy subjects, as shown in Table 1 (Diakidou et al., 2009; Vertzoni 171 
et al., 2010b). For the experimental design, the osmolality was integrated with a low level of 172 
196 mOsmol/kg, corresponding to the osmolality of FaSSCoF and similar to the osmolality 173 
observed in UC patients in relapse, and a high level of 290 mOsmol/kg representative of UC 174 
patients in remission. 175 
The mean total bile acid concentration was lower in UC patients in relapse compared to patients 176 
in remission and healthy subjects as shown in Table 1 but the difference reached no statistical 177 
significance as the power of the test was low (Diakidou et al., 2009; Vertzoni et al., 2010b). 178 
For the experimental design, the bile salt concentration was integrated with a low level of 75 179 
μM representative of UC patients in relapse and a high level of 150 μM (bile salt concentration 180 
of FaSSCoF, similar bile salt concentration in healthy and UC patients in remission). 181 
The concentration of soluble proteins was not significantly different between patients in relapse 182 
and remission but significantly higher compared to healthy subjects [Table 1] (Diakidou et al., 183 
2009; Vertzoni et al., 2010b). For the experimental design, the concentration of soluble proteins 184 
was integrated using bovine serum albumin with a high level of 19 mg/mL representative of 185 
UC patients in relapse and remission and a low level of 0 mg/mL based on the concentration 186 
in FaSSCoF. 187 
9 
 
The lecithin concentrations in the fasted state ascending colon fluid in UC patients in remission 188 
and relapse were in the range of 0.13 to 0.62 mM (graphically extracted) (Vertzoni et al., 189 
2010b). While the mean concentration of lecithin in the fasted state ascending colon fluid of 190 
UC patients was lower compared to healthy subjects, the difference did not reach statistical 191 
significance; a high data variability was observed in this study for the lecithin concentration. 192 
For the experimental design, the lecithin concentration was included as factor with the observed 193 
range as low and high level. 194 
The pH in the fasted state colonic fluid of UC patients was in the range of 5.5 to 7.7 considering 195 
both disease states [Table 1] (Vertzoni et al., 2010b). For the experimental design, the pH was 196 
included as factor with a low level of 5.5 and a high level of 7.7 representative of the pH range 197 
observed in UC patients.  198 
The buffer capacity of the fasted state ascending colon fluid was higher in UC patients in 199 
relapse and remission compared to healthy subjects as measured with hydrochloric acid [Table 200 
1] (Diakidou et al., 2009; Vertzoni et al., 2010b). Due to the high number of factors integrated 201 
in the experimental design for the fasted state colonic UC media, the buffer capacity was not 202 
included. Consequently, the effect of a higher buffer capacity on, for example, weakly acidic 203 
drugs (high dose) that are likely to decrease the luminal pH (depending on the buffer capacity 204 
of the GI fluids), which in turn reduces their luminal solubility, is not captured. 205 
  206 
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Table 1: Overview of characteristics of fasted state ascending colon fluid of UC patients and 207 
healthy subjects and composition of FaSSCoF. 208 
 UC patients in 
relapse 
(Vertzoni et al., 
2010b) 
UC patients in 
remission 
(Vertzoni et al., 
2010b) 
Healthy subjects 
(Diakidou et al., 
2009) 
FaSSCoF 




199.6±127.4 290.1±165.6 80.6±102.5 196 
Concentration 
of bile acid 
[μM] 





18.9±8.1 19.0±10.8 9.8±4.6 0 
pH 6.6 (5.5-7.7) 6.5 (6.1-7.3) 7.8 (6.3-8.4) 7.8 
Buffer capacity 
[mmol/L/ΔpH] 
32.0±18.1 37.7±15.4 21.4±7.9 16 
 209 
3.1.1.3. Fed state colon fluid  210 
Several studies investigated the pH in the colon of UC patients in the fed state (Bosworth et 211 
al., 2009; Ewe et al., 1999; Nugent et al., 2000; Press et al., 1998; Raimundo et al., 1992). Very 212 
low pH values (pH 2.3-3.4) observed in a study by Fallingborg et al. (1993) were excluded due 213 
to analytical uncertainties (e.g., no confirmatory pH measurements, possibly artificial low pH 214 
values when certain distance to antenna was exceeded) (Press et al., 1998). The highest colonic 215 
pH value observed in UC patients in the fed state was 7.8 and the lowest was 4.7 (Press et al., 216 
1998; Raimundo et al., 1992). Therefore, the pH in the fed state colonic medium was included 217 
as factor in the experimental design with a low level of 4.7 and a high level of 7.8 representative 218 
of the pH range observed in UC patients.  219 
3.1.2. Development of UC media with Design of Experiments 220 
A DoE approach was followed to develop the UC biorelevant media with the aim to assess the 221 
impact of each of the factors and to reflect the interindividual variability in UC patients. The 222 
development of UC biorelevant media was based on observed differences in UC patients 223 
compared to healthy subjects identified in literature (Section 3.1.1) and previously developed 224 
11 
 
biorelevant media for healthy subjects including Fasted-State Simulated Gastric Fluid 225 
(FaSSGF), Fasted-State Simulated Intestinal Fluid-Version 2 (FaSSIF-V2), FaSSCoF, Fed-226 
State Simulated Intestinal Fluid-Version 2 (FeSSIF-V2) and Fed-State Simulated Colonic Fluid 227 
(FeSSCoF) (Jantratid et al., 2008; Markopoulos et al., 2015; Vertzoni et al., 2010a; Vertzoni et 228 
al., 2005). 229 
The DoE was performed using XLSTAT (Addinsoft, France) with a full factorial design in UC 230 
patients for stomach and intestine in the fasted state and intestine and colon in the fed state. For 231 
fasted gastric and fasted and fed intestinal media, the lecithin concentration was included as a 232 
factor in the experimental design. Additionally, the ratio of bile salts to lecithin was integrated 233 
as a factor and set to the ratio in the corresponding biorelevant media based on healthy subjects 234 
for the low level. This approach was used to keep a similar composition of the mixed micelles 235 
as in healthy biorelevant media in some UC media. For fed state colonic UC media, the pH and 236 
the concentration of lecithin and bile salts were the investigated factors. 237 
For fasted state colonic UC media, the factors investigated were bile salts, lecithin, pH, 238 
osmolality and soluble proteins. Due to the high number of factors, a fractional factorial design 239 
(2^(5-2)) was used for the UC fasted state colonic media using Dataplot (NIST, US) (Heckert 240 
and Filliben, 2003). The factor soluble proteins was represented in the UC media by bovine 241 
serum albumin. 242 
Each factor changed in UC compared to healthy subjects was integrated in the DoE with two 243 
levels (low and high). Additionally, centre points with medium levels of each parameter were 244 
included for gastric and intestinal media. An overview of the factors and levels of the DoE is 245 
given in Figure 1. For UC-FaSSCoF media with osmolality as factor in the DoE, sodium 246 
chloride was added to adjust the osmolality. For all other media, the osmolality was set to the 247 
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value in corresponding biorelevant media based on healthy subjects by adjusting the 248 
concentration of sodium chloride.  249 
Biorelevant media were prepared according to the method described in Jantratid et al. (2008) 250 
for gastric and intestinal media and Vertzoni et al. (2010a) for colonic media. 251 
3.2. Media characterisation 252 
Surface tension, osmolality, dynamic viscosity and buffer capacity of biorelevant media 253 
previously developed based on healthy subjects and newly developed for UC patients were 254 
measured. All measurements were performed in triplicate. The results were reported as mean 255 
with standard deviation. 256 
3.2.1. Surface tension 257 
Surface tension measurements were performed with a ring tensiometer (Sigma 700 Force 258 
tensiometer, Attension, UK) and a glass vessel (diameter of 46 mm) filled with 10 mL of each 259 
medium at room temperature. The force to pull a Du Noüy ring from the surface of the medium 260 
was measured and related to the medium’s surface tension (Butt et al., 2004). 261 
3.2.2. Osmolality 262 
Osmolality was determined with an Advanced Instruments Inc. micro-osmometer Model 3300 263 
(Norwood, MA, US) by measuring the freezing-point depression of a 20 µl sample.  264 
3.2.3. Dynamic viscosity 265 
A Bohlin Rheometer C-VOR (Malvern instruments, UK) with a cone-plate system (4°, 40mm) 266 
was used to determine the dynamic viscosity of the media at a temperature of 37⁰C. A small 267 
amount of sample was placed between the plate and the cone, sheared with different shear 268 
stresses (20 points, logarithmically distributed between 0.05 and 0.15 Pa) and the shear rate 269 
was measured. Dynamic viscosity corresponds to the ratio of shear stress to shear rate.  270 
3.2.4. Buffer capacity 271 
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To determine the buffer capacity of the media, small volumes of 0.5 M hydrochloric acid were 272 
added to 10 mL of medium until a change of one pH unit was measured with a Mettler Toledo 273 
SevenCompact S220 pH meter (Schwerzenbach, Switzerland). Subsequently, equation (2) was 274 







                   (2) 276 
where β is the buffer capacity, Macid is the molarity of the acid, ΔpH is the change in pH and 277 
Vacid and Vsample are the volume of the acid added and the volume of the sample, respectively 278 
(Rabbie et al., 2015). 279 
3.3. Compound selection 280 
Table 2: Properties of selected compounds for solubility studies. 281 
Drug pKa (acid/base) logP BCS class Intrinsic aqueous 
solubility [mg/mL] 




(Hansch et al., 
1995) 
IV  
(Lindenberg et al., 2004) 
0.171 
(Llinas et al., 2008) 




(Bharate et al., 
2016) 
II  
(Bhatt et al., 2014) 
0.028 
(Ali et al., 2010) 
Celecoxib 11.1 (acid)  
(G.D. Searle LLC 
Division of Pfizer 
Inc, 2019) 
3.5  
(G.D. Searle LLC 
Division of Pfizer 
Inc, 2019) 
II  
(Paulson et al., 2001) 
0.003 - 0.007 
(Paulson et al., 
2001) 






(Zaki et al., 2010) 
0.003 
(Hopfinger et al., 
2009) 
Loperamide 8.6 (base)  
(Manallack, 2007) 
5.5  
(Dickson et al., 
2017) 
II  
(Zaki et al., 2010) 
 
Sulfasalazine 2.3, 7.9 (acid)  
(Shalaeva et al., 
2008)  
2.9  
(Graham and Pile, 
2015) 
II/IV  
(Lindenberg et al., 2004) 
0.29 x 10-3 
(Llinas et al., 2008) 
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For the solubility studies, poorly soluble compounds belonging to class II (low solubility, high 282 
permeability) or IV (low solubility, low permeability) of the Biopharmaceutics Classification 283 
System (BCS) were selected as presented in Table 2. Azathioprine, budesonide and 284 
sulfasalazine are used for the treatment of UC and loperamide can be used as symptomatic 285 
treatment of diarrhoea. Additionally, drugs were selected based on their physicochemical 286 
characteristics, covering a range of ionization properties (pKa) and lipophilicity (logP). 287 
Therefore, several moderately lipophilic drugs were included: dipyridamole and loperamide as 288 
weak bases and sulfasalazine as weak acid. Additionally, we included drugs that were mainly 289 
neutral over the physiological pH range but varied in their lipophilicity: azathioprine, 290 
budesonide and celecoxib. Due to the pKa of 7.9, azathioprine is neutral in gastric and intestinal 291 
media, whereas it was considered as weak acid for the colonic media.  292 
3.4. Solubility studies 293 
The shake-flask method was used to determine the solubility of the six investigated drugs (Baka 294 
et al., 2008). Therefore, 5 mL of medium were added to an excess amount of drug in a glass 295 
tube and placed in a shaking water bath (Grant instruments, UK) at 37 °C with 200 strokes/min. 296 
After 24 h, the supernatant was filtered with GF/D membrane filters with a pore size of 2.7 μm 297 
(Whatman® Puradisc, diameter 13 mm) and analysed by HPLC/UV. HPLC analysis was 298 
performed with an Agilent Technologies 1200 series HPLC system (Santa Clara, CA, US) with 299 
a binary pump, autosampler, thermostatted column compartment and diode array detector. The 300 
details of the HPLC-UV methods used for the quantitative analysis of the six compounds are 301 
described in Effinger et al. (2020). 302 
For biorelevant media including bovine serum albumin, an additional treatment step for protein 303 
precipitation was added after sample filtration. 1 mL of protein precipitation reagent was added 304 
to 500 μL of sample, the mixture was vortexed for 30 s and centrifuged for 10 min at 12000 rpm 305 
and 4°C (Eppendorf Heraeus Fresco 17 centrifuge, ThermoElectron LED GmbH, Germany). 306 
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The protein precipitation reagent was methanol for all drugs except sulfasalazine, for which 307 
dimethyl sulfoxide was used due to the poor solubility of sulfasalazine in methanol. For the 308 
sulfasalazine samples with dimethyl sulfoxide, the ratio of the mobile phase used for the HPLC-309 
UV analysis was modified to 60:40 MeOH: Acetic acid 3.3% in H2O. Solubility studies were 310 
performed in triplicate in UC media and healthy media. Average solubility differences between 311 
UC media and healthy media were expressed as a % Relative effect on solubility [((SUC-312 
SHealthy)/ SHealthy) x 100]. Positive values indicate that drug solubility in UC media exceeds the 313 
solubility in healthy media, whereas negative values indicate the opposite.  314 
3.5. Statistical analysis 315 
All statistical analysis was performed using XLSTAT (Addinsoft, France). To identify 316 
statistically significant differences of media properties and drug solubility between UC 317 
biorelevant media and the corresponding healthy media, one-way analysis of variance 318 
(ANOVA) with a post-hoc Tukey’s test was applied with a significance level of p≤0.05. 319 
Multivariate statistical analysis was used to identify drug properties that result in a high risk of 320 
altered drug solubility in UC. Therefore, the % Relative effect on drug solubility was correlated 321 
with media-dependent factors of the DoE and drug physicochemical properties by Partial Least 322 
Squares (PLS) regression. Media-dependent factors were for gastric and intestinal UC media 323 
the bile salt and lecithin concentration. For fasted state colonic UC media, the media-dependent 324 
factors were osmolality, pH and the concentrations of bile salts, of lecithin and of soluble 325 
proteins. For fed state colonic UC media, media-dependent factors were pH and bile salt and 326 
lecithin concentration. In terms of drug-dependent parameters, the partition coefficient, log P, 327 
was included for all UC media. For media with pH as media-dependent factor (colonic UC 328 
media), a categorical variable discriminating between weak acids, weak bases and neutral 329 
compounds was introduced. For the gastric and intestinal UC media, the % Fraction ionised 330 
(calculated using Advanced Chemistry Development, Inc. (ACD/Labs) Software V11.02, 331 
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Toronto, On, Canada and defined for anionic species as negative and cationic species as 332 
positive) was used as additional drug-dependent factor (Advanced Chemistry Development 333 
Inc., 2019). Interactions between media-dependent and drug-dependent factors were included 334 
in the model as shown in Table 3.  335 
The quality assessment of the PLS models was based on the square of coefficient of 336 
determination (r2) and goodness of prediction (q2), both indicating a good fit of the data and a 337 
good predictive ability of the model, respectively, when close to 1. A difference higher than 338 
0.3 between r2 and q2 indicates model over-fitting and consequently an inappropriate model 339 
(Eriksson et al., 2008). Models were selected for optimum model predictive ability based on 340 
the lowest predicted residual error sum of squares (PRESS) and the highest q2. Usually good 341 
model predictability is given when q2 is higher than 0.5, in certain cases, however, lower limits 342 
can be accepted since q2 is dependent on the properties of the data set e.g., number of 343 
observations (Triba et al., 2015). In our models, a high influence on the % Relative effect on 344 
solubility is indicated for the media- and drug-dependent factors with high absolute value of 345 
the standardised coefficients. If the standardised coefficient is positive, this indicates a positive 346 
effect on the % Relative effect on solubility, while a negative standardised coefficient indicates 347 
the opposite. The Variable Importance in Projection (VIP) of a factor summarizes the influence 348 
of each individual independent factor on the PLS model. Factors with VIP ≥0.7 are considered 349 
as influential to the model, with the factors with a VIP>1 considered as most influential (Chong 350 
and Jun, 2005; Eriksson et al., 2008).  351 
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4. Results and discussion 354 
4.1. Media characterisation 355 
The surface tension and osmolality of healthy and UC biorelevant media are presented in 356 
Figure 2. 357 
Surface tension in fasted state gastric media was significantly higher (+24%, p<0.05) in the UC 358 
medium with low lecithin and low bile salt concentrations compared to the healthy medium, 359 
possibly due to the low surfactant concentration being below the critical micellar concentration. 360 
In fasted state intestinal media, a significantly higher surface tension compared to the healthy 361 
medium was observed for both UC media with low lecithin concentrations (+4%, +15%, 362 
p<0.05). In fasted state simulated colonic media, the surface tension in three UC media with 363 
low pH (low lecithin/low bile salt/low osmolality/high soluble proteins -11%, low lecithin/high 364 
bile salt/high osmolality/low soluble proteins -26% and high lecithin/low bile salt/high 365 
osmolality/low soluble proteins -31%, p <0.05) was significantly lower compared to the 366 
healthy medium and the surface tension of one UC medium (low lecithin/low bile salt/high 367 
pH/high osmolality/high soluble proteins) was increased by 7% (p <0.05). The surface tension 368 
of UC-FaSSCoF media was in the range of 29.3 mN/m to 46.0 mN/m, which is in accordance 369 
with the surface tension observed in the ascending colon fluid of UC patients in relapse 370 
(41.6±3.1 mN/m) and in remission (40.6±3.4 mN/m) (Vertzoni et al., 2010b). In the fed state, 371 
the surface tension of intestinal UC media was significantly decreased compared to the healthy 372 
medium (-7 to -12%, p<0.05). The surface tension of FeSSCoF was significantly higher 373 
compared to six of the UC media including the media with low pH and media with high pH/low 374 
lecithin concentrations (p<0.05). The lower surface tension of the media with low pH could 375 
either be related to the different pH value or the different ion concentration (higher 376 
concentration of sodium chloride) resulting in salt-surfactant synergistic effects that reduce the 377 
surface tension (Alonso et al., 2020). 378 
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Osmolality in UC biorelevant media was only different according to the specified levels for 379 
fasted state colonic media when osmolality was included as factor in the experimental design 380 
(Figure 2).  381 
The dynamic viscosity of the investigated biorelevant media is presented at three different shear 382 
stresses in Figure 3. All healthy and UC media showed pseudoplastic behaviour. The viscosity 383 
at an applied shear stress of 0.15 Pa was in the range of 3.23 to 3.50 mPas, at 0.08 Pa in the 384 
range of 3.74 to 4.28 mPas and at 0.06 Pa in the range of 4.59 to 5.99 mPas, respectively. 385 
Significant differences between biorelevant media based on UC patients and healthy subjects 386 
for all three different shear stresses were not observed (p<0.05).  387 
The buffer capacity was not significantly different in healthy fasted and fed state intestinal 388 
media compared to UC media (Figure 4). In fasted state colonic media, the healthy medium 389 
had a significantly lower buffer capacity compared to all UC media (p<0.05) and the increase 390 
was more pronounced for UC-FaSSCoF media with low pH compared to UC-FaSSCoF media 391 
with high pH. In contrast, in the fed state colonic media the buffer capacity was significantly 392 
lower in the UC media (p<0.05), whereby the decrease was more pronounced for UC-FeSSCoF 393 
media with low pH compared to UC-FeSSCoF media with high pH.  394 
4.2. Solubility of drugs in UC biorelevant media 395 
The % Relative effect of UC on the solubility of six different drugs, as investigated with 396 
biorelevant media based on UC patients and healthy subjects simulating stomach, small 397 
intestine and colon in the fasted state and small intestine and colon in the fed state, is shown in 398 
Figure 5. 399 
4.2.1. Neutral drugs 400 
For all investigated neutral drugs, the final pH of the UC media after 24 h was similar to the 401 
initial pH of the media (within a standard deviation of 0.1). Differences in drug solubility in 402 
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gastric and intestinal media were observed for the investigated neutral drugs due to decreased 403 
lecithin or bile salt concentrations. For budesonide, the decrease was significant in all gastric 404 
fasted state UC media, in the fasted state intestinal UC medium with low lecithin and high bile 405 
salt concentrations and in the fed state intestinal medium with low lecithin and low bile salt 406 
concentrations (p<0.05). For celecoxib, a significantly reduced solubility was observed in the 407 
fasted state gastric UC medium with low lecithin and low bile salt concentrations and in all 408 
fasted and fed state intestinal UC media (p<0.05). These findings are consistent with lower 409 
concentrations of bile salts and lecithin resulting in a decreased concentration of mixed micelles 410 
available for drug solubilisation of lipophilic compounds (Wiedmann and Kamel, 2002).  411 
In fasted state colonic UC media, budesonide solubility was significantly higher in media with 412 
high pH, high osmolality and high soluble proteins (p<0.05). For celecoxib, the solubility was 413 
increased in all UC media with high concentrations of soluble proteins and one other UC 414 
medium (high bile salt and lecithin concentrations, high pH, low concentration of soluble 415 
proteins and a low osmolality), while the solubility was decreased in media with low 416 
concentrations of lecithin and soluble proteins (p<0.05). The positive effect of soluble proteins, 417 
represented by bovine serum albumin, on the solubility of non-ionised compounds has 418 
previously been reported for danazol, felodipine and prednisolone (Fadda et al., 2010; Vertzoni 419 
et al., 2010a). Additionally, it was shown that the octanol:water partition coefficient is 420 
positively correlated to the BSA:water partition coefficient for neutral compounds (Endo and 421 
Goss, 2011). In fed state colonic media, the solubility of budesonide and celecoxib was 422 
significantly decreased in UC media with low lecithin concentrations (p<0.05) indicating lower 423 
solubilisation due to decreased surfactant concentration. For celecoxib, this was also the case 424 
for UC media with low pH. This could be due to the low pH (4.7) resulting in more sodium 425 
cholate (pKa 5.13) being present in its unionised form and hindering the formation of micelles 426 
(Posa et al., 2017). 427 
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4.2.2. Weak bases 428 
For the investigated weak bases, no significant differences in drug solubilisation were observed 429 
in fasted state gastric UC media. For the dipyridamole studies, the pH of the medium at the end 430 
of the solubility studies was increased in fasted state gastric media (pH: 3.0 ± 0.1). The 431 
solubility of loperamide hydrochloride was decreased in all fasted state intestinal UC media 432 
(p<0.05) indicating a lower solubility with a lower concentration of surfactants. For 433 
dipyridamole, a lower solubility was observed in UC-FaSSIF with low lecithin and low bile 434 
salt concentrations, while the solubility was increased in UC-FaSSIF with high bile salt 435 
concentrations and either low or medium lecithin concentration (p<0.05). For dipyridamole, 436 
lower lecithin concentrations seem to promote the solubilisation of dipyridamole, probably due 437 
to electrostatic interactions between dipyridamole and bile salts (Borissevitch et al., 1995). In 438 
fed state intestinal media, the solubility of loperamide hydrochloride was decreased in UC-439 
FeSSIF with low lecithin concentrations and medium lecithin and medium bile salt 440 
concentrations. For dipyridamole, the solubility was decreased in UC-FeSSIF with low and 441 
medium bile salt concentrations indicating again the importance of bile salts for the 442 
solubilisation of weak bases. In fasted state colonic media, the solubility of loperamide 443 
hydrochloride and dipyridamole was increased in media with low pH due to a higher ionised 444 
fraction of the drug. Additionally, the solubility of dipyridamole was also increased in the UC-445 
FaSSCoF media with high level of all factors. In fed state colonic media, loperamide 446 
hydrochloride had a lower solubility in all UC media with high pH due to a smaller protonated 447 
fraction of the drug. Similarly, the solubility of dipyridamole was increased in UC media with 448 
low pH due to a higher fraction ionised. Additionally, loperamide hydrochloride had a higher 449 
solubility in UC-FeSSCoF with high bile salt and low lecithin concentrations and low pH. The 450 
solubility of dipyridamole was decreased in the UC-FeSSCoF media with high pH and low 451 
lecithin concentrations. 452 
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4.2.3. Weak acids 453 
For the investigated weak acids, most differences were observed due to pH changes. For 454 
azathioprine, a hydrophilic compound with a log P of 0.1, the solubility was significantly 455 
decreased in UC-FaSSCoF with low pH, while the solubility was increased in UC-FeSSCoF 456 
with high pH. For sulfasalazine, the solubility in the fasted state gastric media was below the 457 
limit of quantification. In intestinal fasted and fed state media, the solubility of sulfasalazine 458 
was significantly decreased in UC media with low lecithin and low bile salt concentration and 459 
medium lecithin and medium bile salt concentration. In fasted state colonic media, 460 
sulfasalazine solubility was decreased in UC media with low pH and other media with high 461 
pH, low osmolality and low concentration of soluble proteins. In fed state colonic media, the 462 
solubility of sulfasalazine was increased in UC media with high pH and decreased in UC media 463 
with low pH. Differences in the pH of the investigated media compared to their initial pH were 464 
observed in some UC media for the sulfasalazine studies (final pH in UC-FaSSIF 6.2± 0.1, 465 




4.3. Multivariate statistical analysis 468 
Successful PLS models were developed for small intestinal and colonic UC media in the fasted 469 
and fed state. The plots of the standardised coefficients of the respective drug- and media-470 
dependent factors are shown in Figure 6. For the fasted state gastric media, it was not possible 471 
to develop a predictive PLS model (q2 -0.04, r2 0.09).  472 
For fasted state intestinal media, the developed PLS model for the % Relative effect of UC on 473 
drug solubility showed a good fit of the experimental data (r2 0.76) and a high predictive power 474 
(q2 0.70). The model depicted a positive effect of bile salts, lecithin and the interaction between 475 
lecithin and log P, while log P had a negative impact. Consequently, in the luminal fluids of 476 
UC patients with low bile salt and lecithin concentrations a high risk of reduced drug solubility 477 
is expected for compounds with a high lipophilicity. This is in accordance with another study, 478 
where a positive effect of bile salt and lecithin concentration on drug solubility in fasted state 479 
simulated fluids has previously been shown for seven out of twelve compounds with a clogP 480 
in the range of 1.43 to 6.15 (ACD/Labs) including three neutral compounds (felodipine clogP 481 
4.83, griseofulvin clogP 3.53, fenofibrate clogP 4.80), three weak bases (tadalafil clogP 1.43, 482 
zafirlukast clogP 6.15, aprepitant clogP 4.80) and one weak acid (phenytoin clogP 2.52) 483 
(Advanced Chemistry Development Inc., 2019; Khadra et al., 2015). It should be noted that 484 
five drugs  with a clogP of 1.71-10.27 (ACD/Labs) (probucol clogP 10.27, carvedilol clogP 485 
4.11, piroxicam clogP 1.71, indomethacin clogP 3.1, naproxen clogP 3.0) didn’t follow this 486 
pattern in the respective study indicating drug-specific effects in certain cases (Khadra et al., 487 
2015). Therefore, a difference in luminal drug solubility in UC patients may not be fully 488 
predicted for certain drugs by the sole use of drug properties employed in the current study. 489 
For fed state intestinal media, the model quality of the developed PLS model was accurate with 490 
a high predictability (r2 0.73, q2 0.66). As for the PLS model of the fasted state, bile salts and 491 
lecithin had a positive effect on the % Relative effect on drug solubility with a higher impact 492 
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of the bile salt concentration. The interaction between lecithin and log P had also a positive 493 
influence (VIP>0.7). In contrast, log P had a negative impact. In another study, a positive 494 
impact of higher bile salt concentration on drug solubility in fed state simulated intestinal media 495 
was observed for nine of thirteen compounds (itraconazole, probucol, felodipine, tadalafil, 496 
aprepitant, carvedilol, zafirlukast, indomethacin, phenytoin) with a clogP in the range of 1.43 497 
to 10.27 (ACD/Labs) (Zhou et al., 2017). In the same study, a positive effect of lecithin on the 498 
solubility of eight out of thirteen compounds was also observed (itraconazole, probucol, 499 
felodipine, fenofibrate, carvedilol, zafirlukast, indomethacin, phenytoin) (Zhou et al., 2017). 500 
However, bile salts or lecithin had a negative impact on drug solubility for certain lipophilic 501 
drugs in the respective study indicating again drug-specific effects in some cases (Zhou et al., 502 
2017). 503 
For fasted state colonic media, the PLS model with good model quality (r2 0.90, q2 0.82) 504 
revealed a positive effect of log P, weak base and the interplay between soluble proteins and 505 
neutral drugs and a lower positive influence (VIP>0.7) of soluble proteins and the interplay 506 
between log P and neutral drugs. In contrast, the model showed a negative influence of pH, 507 
weak acids, the interplay between pH and log P and the interplay between pH and weak base. 508 
This indicates that differences in drug ionisation determine the drug solubility in the fasted 509 
state colonic fluid of UC patients. Additionally, a higher drug solubility of neutral lipophilic 510 
compounds is expected in the fasted state colonic fluids of UC patients. 511 
For fed state colonic media, the predictive power of the developed PLS model was acceptable 512 
(q2 0.49, r2 0.71). Most influential variables of the model with positive impact were the 513 
categorical variable weak acid and the interplay between pH/logP and pH/weak acid. 514 
Additionally, a positive effect of log P was influential to the model (VIP>0.7). A negative 515 
impact on the % Relative effect on drug solubility was observed for the categorical variable 516 
neutral and the interplay between pH and weak base. Differences in ionisation are therefore, 517 
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expected to be the major influence on drug solubility in the fed state colonic fluid of UC 518 
patients. 519 
Given the high number of UC media and the solubility studies of six compounds, the statistical 520 
models were acceptable. Further studies with more compounds would additionally increase the 521 
confidence in the models. 522 
4.4. Drugs at risk of altered solubility in luminal fluids of UC patients 523 
Considering intestinal fluids in the fasted and fed state, compounds with a higher lipophilicity 524 
are expected to show a lower drug solubility in UC patients compared to healthy subjects. This 525 
is especially expected for UC patients with low concentrations of bile salts and lecithin in their 526 
intestinal fluids. 527 
In terms of fasted state colonic fluids of UC patients, a high risk of altered drug solubility is 528 
indicated for weak bases and weak acids. For weak acids, a lower drug solubility is expected 529 
in fasted state colonic fluids of UC patients compared to healthy subjects. For weak bases, a 530 
higher drug solubility is expected in UC patients with a low pH in their fasted state colonic 531 
fluids. Additionally, neutral moderately lipophilic drugs are expected to have a higher 532 
solubility in UC patients with increased concentrations of soluble proteins (relapse and 533 
remission) in their fasted state colonic fluids. 534 
Regarding the fed state colonic fluid of UC patients, the altered colonic pH in UC patients 535 
poses a risk for ionisable drugs. For weak acids, a higher drug solubility is expected in UC 536 
patients with increased pH in their fed state colonic fluids, whereas for weak bases a lower 537 
drug solubility is expected. In addition, a lower solubility of neutral moderately lipophilic drugs 538 
is expected in the fed state colonic fluids of UC patients with low lecithin concentration.  539 
5. Conclusion  540 
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Biorelevant media were developed as an in vitro tool to assess drug solubility and dissolution 541 
in UC patients for different GI compartments and prandial states based on literature data 542 
investigating pathophysiological changes in UC. The characterisation of UC biorelevant media 543 
revealed differences in terms of surface tension, buffer capacity and osmolality compared to 544 
biorelevant media based on healthy subjects. Differences in drug solubility were observed for 545 
the six investigated compounds in UC media compared to biorelevant media based on healthy 546 
subjects and suggest differences in drug ionisation, micellar solubilisation and interaction with 547 
soluble proteins as main influencing factors. Additional studies are needed to characterise the 548 
gastrointestinal fluids of UC patients and solubility studies of additional compounds in UC 549 
biorelevant media would create a bigger database for the biopharmaceutics risk assessment in 550 
UC patients.  551 
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Figure Legends 738 
Figure 1: Design of experiments for the development of Ulcerative Colitis media. 739 
Figure 2: Surface tension (blue, left y-axis) and osmolality (black, right y-axis) of UC 740 
biorelevant media according to the Design of Experiments (green: high level, yellow: 741 
medium level, red: low level, white: healthy level) and healthy media. 742 
Figure 3: Dynamic viscosity of biorelevant media based on UC patients and healthy subjects 743 
at different shear stress (0.06 Pa: blue, 0.08 Pa: red, 0.15 Pa: black) according to the Design 744 
of Experiments (green: high level, yellow: medium level, red: low level, white: healthy 745 
level). 746 
Figure 4: % Relative effect on buffer capacity in biorelevant media based on UC patients 747 
compared to healthy subjects according to the Design of Experiments (green: high level, 748 
yellow: medium level, red: low level). 749 
Figure 5: % Relative effect on solubility of investigated drugs in biorelevant media based on 750 
UC patients compared to healthy subjects according to Design of Experiments for (a) neutral 751 
drugs, (b) weak bases and (c) weak acids (green: high level, yellow: medium level, red: low 752 
level). 753 
Figure 6: Standardised coefficients of the PLS regression of drug solubility in UC simulated 754 
gastrointestinal fluids in the fasted state (left) and fed state (right) and different compartments 755 
of the GI tract (top: small intestine, bottom: colon). Red colour denotes coefficients of VIP 756 
values > 1 and blue > 0.7. 757 
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